InvestSMART

Vectus Biosystems Limited (ASX:VBS)

ALERT: Price-sensitive ASX Announcement for VBS
Current share price for VBS : $0.185 0.035 (23.33%)+
Announcement
Release
28 Jul 2026 5:58PM
Price at Release
$0.150
Full Release
download
Summary
Vectus Biosystems Limited, an Australian biotechnology company, released its quarterly activities report for the period ending 30 June 2026. The company highlighted several key developments including the completion of a $791,000 placement to accelerate clinical trial work for its lead compound VB0004, aimed at treating idiopathic pulmonary fibrosis (IPF). The company also finalized the out-licensing of its VB4-P5 renal compound to XORTX Therapeutics, receiving equity interest in return. Dr. Tara Speranza was appointed as the new CEO and CTO, bringing extensive experience in scientific research and biotechnology commercialization. The company's cash position at the end of the quarter was $718,000, with a focus on reducing operating costs and exploring licensing opportunities. Engagement with Cardinal Health Regulatory Services was initiated to support FDA-related activities for VB0004.
Key Points
  • Appointment of Dr. Tara Speranza as CEO and CTO.
  • Completion of a $791,000 placement for VB0004 clinical trials.
  • Out-licensing of VB4-P5 renal compound to XORTX.
  • Engagement with Cardinal Health Regulatory Services for FDA matters.
  • Focus on reducing operating costs and exploring licensing opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.